FDA approves first new type of pain medication in 25 years
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...
The Washington Post6d
Americans might finally have to face what’s in their food
The proposed label has been a long time in the making. More than 25 years ago, Congress directed federal agencies, including the FDA and the Centers ... are healthy or not, consumers can look ...
Do food warning labels actually work? Answering your questions.
Readers had a lot to say about my latest column on the Food and Drug Administration’s proposed front-of-package labels. Most ...
MedCity News5d
New FDA Approval Adds Chronic Kidney Disease to Ozempic’s Label
and Novo Nordisk can now claim to have the first medication in this class approved for chronic kidney disease. The FDA has expanded the label of Ozempic, approving the Novo Nordisk product for ...
JD Supra6d
FDA Releases Proposed Front-of-Package Nutrition Labeling Rule
FDA has not been alone in this interest. In 2011, in the United States, industry launched its own voluntary labeling program known as “Facts Up Front.” 5 Internationally, there has been rising ...
Nasdaq7d
Supernus Pharmaceuticals Announces FDA Approval for Updated Qelbree Label Including New Pharmacodynamic Data and Lactation Information
The company does not provide detailed information ... announced that the U.S. Food and Drug Administration (FDA) has approved an update for the label for Qelbree (viloxazine extended-release ...
US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...
The American Journal of Managed Care2d
FDA Approves First HER2-Ultralow Companion Diagnostic, Expanding Treatment Eligibility
Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...
GlobalData on MSN12d
J&J’s Spravato receives FDA label expansion for depression monotherapy
The FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.